GSK

Preço: 53.04

Empresa e modelo de negócios

GSK is a global healthcare company focused on pharmaceuticals, vaccines, and consumer healthcare products. Its core products include prescription medications for various therapeutic areas, vaccines for infectious diseases, and over-the-counter consumer health products. Major business segments consist of Pharmaceuticals, Vaccines, and Consumer Healthcare, with revenue primarily generated from prescription drugs and vaccines. The company aims to address health challenges through innovation and research.

Perfil de investimento

GSK's stock presents a neutral investment profile, appealing to investors seeking a balance between growth and dividends. The company offers a moderate dividend yield, which may attract income-focused investors, while its pharmaceutical innovations suggest potential for future growth. However, recent revenue declines indicate caution for growth-oriented investors. Overall, it may suit those looking for stability rather than aggressive growth.

Site oficial

Métricas fundamentais (experimental)

EPS (TTM) — lucro por ação dos últimos 12 meses, $: 3.42 OK
Receita QoQ — crescimento da receita trimestre contra trimestre: -11.5% ↓
Surpresa de EPS: 6.9% melhor que o esperado
Volatilidade 20d: 1.5% estável
Dividend yield: 3.5% moderado última data ex-dividendo: 2026-05-15

Dados FMP / FinFeed atualizados: 2026-06-10

Rec.: Comprar Potencial: 63 Risco: 42 Atualizado: 2026-06-13 02:53

Como a recomendação funciona

Por que a IA pensa assim:

Stable dividend, but revenue decline raises concerns.

Acompanhar no portfólio

Gráfico de preço

Recomendação da IA Previsão do analista Evento de calendário Sinal positivo Sinal negativo Neutro / atualização Manter / informativo B My buy S My sell

Mudanças na recomendação da IA

Data	Antes	Depois	Motivo
2026-06-13 02:53	Manter	Comprar	Stable dividend, but revenue decline raises concerns.
2026-05-28 02:46	Vender	Manter	Weak fundamentals and mixed momentum signal caution.
2026-05-20 02:45	Manter	Vender	Weak fundamentals and negative momentum raise concerns.
2026-05-08 15:09	—	Manter	Weak momentum and fundamentals raise significant risk concerns.
2026-05-08 05:34	Manter	Manter	Компания GSK демонстрирует высокую дивидендную доходность и положительный рост за 120 дней, однако недавние падения цен и отрицательная динамика выручки вызывают опасения.
2026-04-25 02:54	Comprar	Manter	Компания показывает умеренный рост за последние месяцы, однако недавнее снижение цены может указывать на краткосрочные риски. Дивидендная доходность также привлекательна, что делает акцию интересной для долгосрочных инве
2026-03-17 17:10	Manter	Comprar	Компания GSK демонстрирует положительную динамику на длительном горизонте, с ростом на 31.43% за 120 дней, а также стабильный дивидендный доход в 3.30%. Несмотря на недавние колебания, потенциал роста и сильные финансовы
2026-03-09 07:39	Comprar	Manter	Компания GSK демонстрирует устойчивый рост за последние 120 дней, однако недавнее снижение цен и отрицательная динамика выручки могут указывать на краткосрочные риски. Рекомендуется удерживать акции до прояснения ситуаци
2026-01-22 08:35	Manter	Comprar	Компания GSK показывает положительную динамику на длительном горизонте, особенно за последние 120 дней. Несмотря на недавние колебания, её рост и стабильность в секторе здравоохранения делают её привлекательной для инвес

Previsões de analistas

Data	Analista	Action	Alvo	Preço na época
2025-10-30 11:27	CFRA	Atualizar	— → 53	46.67

Stocks to Watch: Nuvalent Soars on GSK Acquisition Announcement, J.M. Smucker Reports Strong Earnings, SailPoint Issues Weak Guidance

06/09/2026, 05:33 AM business review J.M. Smucker Company Micron Technology GSK Alibaba Vail Resorts Qualcomm

Nuvalent's shares surged nearly 39% following GSK's announcement of a $10.6 billion acquisition, highlighting significant market activity in the pharmaceutical sector. Meanwhile, J.M. Smucker's strong earnings report positively impacted its stock, while SailPoint's disappointing guidance led to a notable decline in its shares.

GSK in Negotiations to Acquire Oncology Biotech Nuvalent for Over $9 Billion

06/08/2026, 10:31 PM business announcement GSK

GSK is negotiating to acquire Nuvalent for over $9 billion, marking its largest acquisition in over a decade, which could significantly enhance its oncology portfolio and address investor concerns about its drug pipeline.